<DOC>
	<DOC>NCT00503477</DOC>
	<brief_summary>A Phase I open label dose escalation study to assess the safety and tolerability of AZD2171 following single and multiple oral doses in patients in Japan with advanced solid malignancies. In addition there will be an expanded cohort multi-centre study phase with NSCLC patient and CRC patients</brief_summary>
	<brief_title>A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan</brief_title>
	<detailed_description />
	<mesh_term>Cediranib</mesh_term>
	<criteria>advanced solid tumors life expectancy is 12 weeks or longer patient with uncontrolled brain metastases patient with inappropriate laboratory test values patient with poorly controlled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Japan</keyword>
	<keyword>Phase I</keyword>
	<keyword>solid tumor</keyword>
	<keyword>AZD2171</keyword>
</DOC>